A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment

INTRODUCTION: As patients who receive cannabidiol (CBD) may have co-existing renal morbidities, it is important to understand whether dose adjustments are necessary to mitigate the risk of exposure-related toxicity. This study was conducted to evaluate the pharmacokinetics, safety, and tolerability...

Descripción completa

Detalles Bibliográficos
Autores principales: Tayo, Bola, Taylor, Lesley, Sahebkar, Farhad, Morrison, Gilmour
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292807/
https://www.ncbi.nlm.nih.gov/pubmed/31802404
http://dx.doi.org/10.1007/s40262-019-00841-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292807/
https://www.ncbi.nlm.nih.gov/pubmed/31802404
http://dx.doi.org/10.1007/s40262-019-00841-6

Ejemplares similares